|
gptkbp:instanceOf
|
gptkb:drug
gptkb:kinase_inhibitor
|
|
gptkbp:approvalYear
|
2005
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
L01XE05
|
|
gptkbp:bioavailability
|
38-49%
|
|
gptkbp:brand
|
gptkb:Nexavar
|
|
gptkbp:CASNumber
|
284461-73-0
|
|
gptkbp:contraindication
|
pregnancy
severe hepatic impairment
|
|
gptkbp:developer
|
gptkb:Bayer
gptkb:Onyx_Pharmaceuticals
|
|
gptkbp:discoveredBy
|
gptkb:Bayer
|
|
gptkbp:eliminationHalfLife
|
25-48 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:hasMolecularFormula
|
C21H16ClF3N4O3
|
|
gptkbp:IUPACName
|
4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide
|
|
gptkbp:KEGGID
|
D06402
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits multiple tyrosine protein kinases
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
gptkb:X_(Australia)
D (US)
|
|
gptkbp:proteinBinding
|
99.5%
|
|
gptkbp:PubChem_CID
|
216239
CHEMBL254
DB00398
187186
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
diarrhea
fatigue
hypertension
rash
hand-foot skin reaction
|
|
gptkbp:target
|
gptkb:PDGFR
gptkb:VEGFR
gptkb:FLT3
gptkb:c-KIT
RAF kinases
|
|
gptkbp:UNII
|
81G40H8B0T
|
|
gptkbp:usedFor
|
gptkb:cancer
gptkb:renal_cell_carcinoma
hepatocellular carcinoma
|
|
gptkbp:bfsParent
|
gptkb:Non-Small_Cell_Lung_Cancer
|
|
gptkbp:bfsLayer
|
6
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Sorafenib
|